The first and only BCMA-targeted antibody-drug conjugate (ADC) monotherapy1
Watch our latest videos below with key experts discussing the latest “hot topics” and their implications in patient care.
The evolving treatment landscape and unmet needs in relapsed/refractory multiple myeloma (RRMM)
Dr Karthik Ramasamy discusses the current standard of care in triple refractory multiple myeloma, and the rationale for targeting B-cell maturation antigen (BCMA)
BLENREP (belantamab mafodotin) in triple refractory RRMM: a clinical data review
Dr Rakesh Popat presents the DREAMM-2 study, including key efficacy results, safety data, and patient-reported outcomes data
Monitor, Minimise, Modify: the 3 Ms of corneal AE management
Miss Simona Degli Esposti and Dr Rakesh Popat discuss the practicalities of managing corneal adverse events across the MDT
Real-world patient case studies
Panel discussion and Q&A
Reference
- BLENREP (belantamab mafodotin) Summary of Product Characteristics
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
January 2022 | PM-GB-BLM-WCNT-210003 (V1.0)